Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY20 results · Jul–Sep 2019
Glenmark Pharmaceuticals reported revenue from operations of ₹2,815.04 crore (up 9.1% from Q2 FY19) and net profit of ₹255.54 crore (down 38.3% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,815.04 | 2,581.33 | +9.1% | 2,322.88 | +21.2% |
| Other income | 80.83 | 139.88 | −42.2% | 1.67 | 48x |
| Total income | 2,895.86 | 2,721.21 | +6.4% | 2,324.55 | +24.6% |
| Profit before tax | 347.30 | 579.59 | −40.1% | 159.84 | +117.3% |
| Net profit for the period | 255.54 | 414.00 | −38.3% | 109.28 | +133.8% |
| EPS, basic (₹) | 9.06 | 14.67 | not comparable | 3.87 | not comparable |
| Net margin (%) | 9.1 | 16.0 | 4.7 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,789.82 | 1,679.71 | +6.6% | 1,498.79 | +19.4% |
| Other income | 192.47 | 226.30 | −15.0% | 68.54 | +180.8% |
| Total income | 1,982.29 | 1,906.02 | +4.0% | 1,567.33 | +26.5% |
| Profit before tax | 474.51 | 875.52 | −45.8% | 276.94 | +71.3% |
| Net profit for the period | 431.99 | 747.56 | −42.2% | 227.84 | +89.6% |
| EPS, basic (₹) | 15.31 | 26.49 | not comparable | 8.07 | not comparable |
| Net margin (%) | 24.1 | 44.5 | 15.2 |
Consolidated
- Filed with BSE
- 15 Nov 2019, 18:05 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Nov 2019, 18:05 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE